SmithKline Avandia Launch In EU Delayed By Negative CPMP Vote
Executive Summary
SmithKline Beecham will work with European regulators over the next several months to persuade them to reverse a negative opinion from the Committee for Proprietary Medicinal Products regarding the approval of its antidiabetic Avandia (rosiglitazone).
You may also be interested in...
SmithKline Avandia Recommended Only For Combination Use By CPMP
SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.
SmithKline Avandia Recommended Only For Combination Use By CPMP
SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.
Prozac New Prescription Share Declines; Celexa, Effexor Make Gains
Lilly Prozac's share of new prescriptions declined four percentage points year to date, according to IMS Health data.